Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis
Authors
Panoulas, Vasileios F.Douglas, Karen M. J.
Milionis, Haralampos J.
Metsios, Giorgos S.
Stavropoulos-Kalinoglou, Antonios
Nightingale, Peter
Kita, Marina D.
Elisaf, Moses S.
Kitas, George D.
Issue Date
2008
Metadata
Show full item recordAbstract
OBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors. Hypertension (HT), one of the most common risk factors for cardiovascular disease, is highly prevalent in RA. The effects of long-term glucocorticoid (GC) therapy on blood pressure have not been established yet. This study examined whether GC exposure associates with HT in patients with RA. METHODS: Four hundred consecutive RA patients with detailed clinical and laboratory assessments were categorized into three groups according to GC exposure: no or limited exposure (N/L-E); a low-dose (< 7.5 mg) long-term exposure (LD/LT-E); and medium-dose (> or = 7.5 mg) long-term exposure (MD/LT-E). The association of GC exposure with HT was evaluated using logistic regression analysis. RESULTS: HT was more prevalent in the MD/LT-E group (84.7%) than the LD/LT-E or N/L-E groups (70.7 and 67.3%, respectively, P = 0.028). Logistic regression revealed increased odds for HT when comparing MD/LT-E with N/L-E, after adjustment for HT risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA disease characteristics (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01). CONCLUSIONS: MD/LT GC exposure associates with a very high prevalence of HT. This appears to be independent of other risk factors for HT or of channelling bias due to disease severity, even though the latter cannot be excluded given the cross-sectional nature of our study. RA patients in this GC exposure group should be particularly targeted for early identification and aggressive management of HT.Citation
Rheumatology, 47(1): 72-75Publisher
Oxford University PressJournal
RheumatologyPubMed ID
18077493Additional Links
http://rheumatology.oxfordjournals.org/cgi/content/abstract/47/1/72Type
Journal articleLanguage
enISSN
1462-0332ae974a485f413a2113503eed53cd6c53
10.1093/rheumatology/kem311
Scopus Count
Collections
Related articles
- Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis.
- Authors: Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, Tselios AL, Metsios GS, Elisaf MS, Kitas GD
- Issue date: 2007 Sep
- Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.
- Authors: Toms TE, Panoulas VF, Douglas KM, Griffiths HR, Kitas GD
- Issue date: 2008
- Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis.
- Authors: Panoulas VF, Douglas KM, Milionis HJ, Nightingale P, Kita MD, Klocke R, Metsios GS, Stavropoulos-Kalinoglou A, Elisaf MS, Kitas GD
- Issue date: 2008 Mar
- Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study.
- Authors: Amann J, Wessels AM, Breitenfeldt F, Huscher D, Bijlsma JWJ, Jacobs JWG, Buttgereit F
- Issue date: 2017 May-Jun
- Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis.
- Authors: Schenfeld J, Iles J, Trivedi M, Accortt NA
- Issue date: 2017 Jul